The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer
Open accessAbstract
Background and Aims Although the majority of patients with non-alcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizeable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24–52 weeks, which makes testing for drug response costly and time consuming. Methods We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low weekly dose of intraperitoneal carbon tetrachloride (CCl 4 ), which serves as an accelerator. Results C57BL/6J mice were fed a normal chow diet ± CCl 4 or WD ± CCl 4 for 12 and 24 weeks. Addition of CCl 4 exacerbated histological features of NASH, fibrosis, and tumor development induced by WD, which resulted in stage 3 fibrosis at 12 weeks and HCC development at 24 weeks. Furthermore, whole liver transcriptomic analysis indicated that dysregulated molecular pathways in WD/CCl 4 mice and immunologic features were similar to those of human NASH. Conclusions Our mouse NASH model exhibits rapid progression of advanced fibrosis and HCC, and mimics histological, immunological and transcriptomic features of human NASH, suggesting that it will be a useful experimental tool for preclinical drug testing. Lay summary A carefully characterized model has been developed in mice that recapitulates the progressive stages of human fatty liver disease, from simple steatosis, to inflammation, fibrosis and cancer. The functional pathways of gene expression and immune abnormalities in this model closely resemble human disease. The ease and reproducibility of this model make it ideal to study disease pathogenesis and test new treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the FAT-MASH model was used, as this model reproducibly recapitulates the stages of progression of human MASH that include advanced fibrosis and tumors along with changes in the gut microbiome.14,33,34”
From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“These functions normally contribute to tissue repair under homeostatic conditions, but sustained activation in chronic liver diseases drives fibrosis, especially in MASH (41) where they are detectable by expression of desmin and alpha smooth muscle actin (αSMA) using immunofluorescence, and by conservation of gene expression based on single-cell RNA-seq (42-46).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [45]
In the citing paper
“Our laboratory uses a simple rodent model of MASH, the “FAT-MASH” mouse, which robustly develops Fibrosis and Tumors, features of advanced disease, after 24 weeks of a Western diet combined with a small weekly dose of the liver toxin CCl4 (45).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
A scaling normalization method for differential expression analysis of RNA-seq data
Robinson, M. D., & Oshlack, A. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r25 · Cited by 7,876
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationMaeda, S., Kamata, H., Luo, J., Leffert, H. L., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,160
Cited by
Sorted by citations
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationFrom NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Past, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
The Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells
Trivedi, P., Wang, S., & Friedman, S. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.026 · Cited by 427
Self-citationNAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 452
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Self-citationToxicity of carbon tetrachloride, free radicals and role of antioxidants
Ünsal, V., Çiçek, M., & Sabancılar, İ. (2020) · Reviews on Environmental Health · doi:10.1515/reveh-2020-0048 · Cited by 349
Lipid alterations in chronic liver disease and liver cancer
Paul, B., Lewińska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 326
Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01043-6 · Cited by 262
Self-citationWang, X., He, Q., Zhou, C., Xu, Y., Liu, D., Fujiwara, N., Kubota, N., Click, A., Henderson, P., Vancil, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.11.013 · Cited by 262
Self-citationPreclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Febbraio, M. A., Reibe, S., Shalapour, S., Ooi, G., Watt, M. J., & Karin, M. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.012 · Cited by 250
Tan, J., Fan, W., Liu, T., Zhu, B., Liu, Y., Wang, S., Wu, J. H., Liu, J., Zou, F., Wei, J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.032 · Cited by 261
Animal models for liver disease – A practical approach for translational research
Nevzorova, Y. A., Boyer‐Díaz, Z., Cubero, F. J., & Gracia‐Sancho, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.011 · Cited by 252
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
Brown, Z. J., Heinrich, B., & Greten, T. F. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0033-6 · Cited by 253
Gallagher, E. J., & LeRoith, D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0295-5 · Cited by 241
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C. Y., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 239
Li, F., Huangyang, P., Burrows, M., Guo, K., Riscal, R., Godfrey, J. T., Lee, K. E., Lin, N., Lee, P., Blair, I. A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0511-2 · Cited by 216
Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis
Sun, X., Seidman, J. S., Zhao, P., Troutman, T. D., Spann, N. J., Que, X., Zhou, F., Liao, Z., Pasillas, M. P., Yang, X., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.014 · Cited by 213
A researcher’s guide to preclinical mouse NASH models
Gallage, S., Avila, J. E. B., Ramadori, P., Focaccia, E., Rahbari, M., Ali, A., Malek, N. P., Anstee, Q. M., & Heikenwälder, M. F. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00700-y · Cited by 212
Animal models of drug-induced liver injury
McGill, M. R., & Jaeschke, H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.037 · Cited by 202
Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Morrow, M. R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J. M., Mohammadi-Shemirani, P., Desjardins, E. M., Wang, Z., Tsakiridis, E. E., Lavoie, D. C. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.004 · Cited by 199
Yang, Y., Cai, J., Yang, X., Wang, K., Sun, K., Yang, Z., Zhang, L., Yang, L., Gu, C. P., Huang, X., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.021 · Cited by 198
Im, Y. R., Hunter, H., de Gracia Hahn, D., Duret, A., Cheah, Q., Dong, J., Fairey, M., Hjalmarsson, C., Li, A., Lim, H. K., et al. (2021) · Hepatology · doi:10.1002/hep.31897 · Cited by 195
Parlati, L., Régnier, M., Guillou, H., & Postic, C. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100346 · Cited by 201
Zheng, Y., Wang, S., Wu, J., & Wang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04367-1 · Cited by 197
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
Müller, M., Bird, T. G., & Nault, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.019 · Cited by 182
Wang, S., Li, K., Pickholz, E., Dobie, R., Matchett, K. P., Henderson, N. C., Carrico, C., Driver, I., Borch Jensen, M., Chen, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add3949 · Cited by 176
Self-citationYe, Q., Liu, Y., Zhang, G., Deng, H., Wang, X., Tuo, L., Chen, C., Pan, X., Wu, K., Fan, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37142-3 · Cited by 179
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
Self-citationDeveloping dietary interventions as therapy for cancer
Taylor, S. R., Falcone, J. N., Cantley, L. C., & Goncalves, M. D. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00485-y · Cited by 168
Moreno‐Fernandez, M. E., Giles, D. A., Oates, J. R., Chan, C. C., Damen, M. S. M. A., Doll, J., Stankiewicz, T. E., Chen, X., Chetal, K., Karns, R. A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.018 · Cited by 163
Impacts of exercise interventions on different diseases and organ functions in mice
Guo, S., Huang, Y., Yan, Z., Huang, H., Hong, S., & Liu, T. (2019) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2019.07.004 · Cited by 159
Wabitsch, S., McCallen, J., Kamenyeva, O., Ruf, B., McVey, J. C., Kabát, J., Walz, J. S., Rotman, Y., Bauer, K. C., Craig, A. J., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.010 · Cited by 147
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Ma, X., Huang, T., Chen, X., Li, Q., Liao, M., Fu, L., Huang, J., Yuan, K., Wang, Z., & Zeng, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02104-8 · Cited by 133
Loft, A., Alfaro, A. J., Schmidt, S. F., Pedersen, F. B., Terkelsen, M. K., Puglia, M., Chow, K. K., Feuchtinger, A., Troullinaki, M., Maida, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.06.005 · Cited by 129
Cell type- and tissue-specific functions of ecto-5′-nucleotidase (CD73)
Minor, M., Alcedo, K. P., Battaglia, R. A., & Snider, N. T. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00285.2019 · Cited by 132
Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research
Flessa, C., Ansari, N. N., Kyrou, I., Leca, B. M., Lianou, M., Chatzigeorgiou, A., Kaltsas, G., Kassi, E. N., & Randeva, H. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415791 · Cited by 141
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 138
Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take
Altea‐Manzano, P., Cuadros, A. M., Broadfield, L. A., & Fendt, S. (2020) · EMBO Reports · doi:10.15252/embr.202050635 · Cited by 123
Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential
Deng, C., Zhu, N., Zhao, T., Li, H., Gu, J., Liao, D., & Li, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.803473 · Cited by 113
Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis
Zhu, C., Tabas, I., Schwabe, R. F., & Pajvani, U. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00365-6 · Cited by 112
Lysyl Oxidase‐Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis
Tan, H., Wang, N., Zhang, C., Chan, Y.-T., Yuen, M., & Feng, Y. (2020) · Hepatology · doi:10.1002/hep.31600 · Cited by 114
Tao, L., Yang, X., Ge, C., Zhang, P., He, W., Xu, X., Li, X., Chen, W., Yu, Y., Zhang, H., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.013 · Cited by 114
Martí-Rodrigo, A., Alegre, F., Moragrega, Á. B., Garcia‐García, F., Martí‐Rodrigo, P., Fernández‐Iglesias, A., Gracia‐Sancho, J., Apostolova, N., Esplugues, J. V., & Blas‐García, A. (2019) · Gut · doi:10.1136/gutjnl-2019-318372 · Cited by 110
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC
Xia, Y., Wang, Y., Xiong, Q., He, J., Wang, H., Islam, M., Zhou, X., Kim, A. C., Zhang, H., Huang, H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000762 · Cited by 116
Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice
Dalwadi, D. A., Torrens, L., Abril‐Fornaguera, J., Pinyol, R., Willoughby, C. E., Posey, J., Llovet, J. M., Lanciault, C., Russell, D. W., Grompe, M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.018 · Cited by 106
Qing, J., Ren, Y., Zhang, Y., Yan, M., Zhang, H., Wu, D., Ma, Y., Chen, Y., Huang, X., Wu, Q., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.032 · Cited by 106
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD
Ma, C., Fu, Q., Diggs, L. P., McVey, J. C., McCallen, J., Wabitsch, S., Ruf, B., Brown, Z. J., Heinrich, B., Zhang, Q., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.004 · Cited by 101
de l’Hortet, A. C., Takeishi, K., Guzman‐Lepe, J., Morita, K., Achreja, A., Popovic, B., Wang, Y., Handa, K., Mittal, A., Meurs, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.017 · Cited by 106
Animal and Organoid Models of Liver Fibrosis
Bao, Y., Wang, L., Pan, H., Zhang, T.-R., Chen, Y., Xu, S.-J., Mao, X., & Li, S.-W. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.666138 · Cited by 101
Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
Fang, T., Wang, H., Pan, X., Little, P. J., Xu, S., & Weng, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65044 · Cited by 107
Proliferative polyploid cells give rise to tumors via ploidy reduction
Matsumoto, T., Wakefield, L., Peters, A. M., Peto, M., Spellman, P. T., & Grompe, M. (2021) · Nature Communications · doi:10.1038/s41467-021-20916-y · Cited by 101
In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
Lee, Y., & Seki, E. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.05.010 · Cited by 102
Self-citationYashaswini, C. N., Qin, T., Bhattacharya, D., Amor, C., Lowe, S. W., Lujambio, A., Wang, S., & Friedman, S. L. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.03.014 · Cited by 90
Self-citationWei, G., An, P., Vaid, K. A., Nasser, I., Huang, P., Tan, L., Zhao, S., Schuppan, D., & Popov, Y. V. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00041.2019 · Cited by 84
Watanabe, T., Tsuchiya, A., Takeuchi, S., Nojiri, S., Yoshida, T., Ogawa, M., Itoh, M., Takamura, M., Suganami, T., Ogawa, Y., et al. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.03.012 · Cited by 87
Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2
Liu, B., Xiang, L., Ji, J., Liu, W., Chen, Y., Xia, M., Liu, Y., Liu, W., Zhu, P., Jin, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144801 · Cited by 85
How to calculate sample size in animal and human studies
Zhang, X., & Hartmann, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1215927 · Cited by 81
Alshawsh, M. A., Alsalahi, A., Alshehade, S. A., Saghir, S. A. M., Ahmeda, A. F., Al Zarzour, R. H., & Mahmoud, A. M. (2022) · Molecules · doi:10.3390/molecules27030858 · Cited by 81
Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
Ganbold, M., Owada, Y., Ozawa, Y., Shimamoto, Y., Ferdousi, F., Tominaga, K., Zheng, Y., Ohkohchi, N., & Isoda, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-52736-y · Cited by 81
Guo, W., Ge, X., Lü, J., Xu, X. P., Gao, J., Wang, Q., Song, C., Zhang, Q., & Yu, C. (2022) · Nutrients · doi:10.3390/nu14245335 · Cited by 78
Zhang, Y., Xie, R., Dai, C.-S., Gao, H., Zhou, G., Qi, T., Wang, W.-Y., Wang, H., & Yi-min, C. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.008 · Cited by 77
Wang, Z., Zhu, S., Jia, Y., Wang, Y., Kubota, N., Fujiwara, N., Gordillo, R., Lewis, C., Zhu, M., Sharma, T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.014 · Cited by 72
Self-citationWang, Y., Tai, Y., Zhao, D., Zhang, Y., Yan, J., Kakiyama, G., Wang, X., Gurley, E. C., Liu, J., Liu, J., et al. (2021) · Cells · doi:10.3390/cells10020210 · Cited by 69
Svobodová, G., Horní, M., Velecká, E., & Boušová, I. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03889-x · Cited by 72
An update on animal models of liver fibrosis
Wu, S., Wang, X., Xing, W., Li, F., Liang, M., Li, K., He, Y., & Wang, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1160053 · Cited by 71
Chen, K., Ma, J., Jia, X., Ai, W., Ma, Z., & Pan, Q. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.005 · Cited by 72
Wang, Y.-F., Zhang, W.-L., Li, Z.-X., Liu, Y., Tan, J., Yin, H.-Z., Zhang, Z.-C., Piao, X.-J., Ruan, M.-H., Dai, Z.-H., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01797-1 · Cited by 69
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells
Endo‐Umeda, K., & Makishima, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205045 · Cited by 68
Deng, Y., Xu, Q., Chen, T., Ming, J., Wang, Y., Mao, L., Zhou, J., Sun, W., Zhou, Q. Y., Ren, H. G., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154241 · Cited by 71
NAFLD Preclinical Models: More than a Handful, Less of a Concern?
Oligschlaeger, Y., & Shiri‐Sverdlov, R. (2020) · Biomedicines · doi:10.3390/biomedicines8020028 · Cited by 71
Zhang, H., Ma, Y., Cheng, X., Wu, D., Huang, X., Chen, B., Ren, Y., Jiang, W., Tang, X., Bai, T., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1206 · Cited by 65
Self-citationLiu, G., Cui, Z., Gao, X., Liu, H., Wang, L., Gong, J., Wang, A., Zhang, J., Ma, Q., Huang, Y., et al. (2021) · Phytotherapy Research · doi:10.1002/ptr.7195 · Cited by 65
Protective effects of polysaccharides on hepatic injury: A review
Yuan, Y., Che, L., Qi, C., & Meng, Z. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.09.002 · Cited by 65
MicroRNA-26b-5p Inhibits Mouse Liver Fibrogenesis and Angiogenesis by Targeting PDGF Receptor-Beta
Yang, L., Dong, C., Yang, J., Yang, L., Chang, N., Qi, C., & Li, L. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.014 · Cited by 63
Recent update on application of dihydromyricetin in metabolic related diseases
Wang, Y., Wang, J., Xiang, H., Ding, P., Wu, T., & Ji, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112771 · Cited by 62
HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia
Povero, D., Chen, Y., Johnson, S. M., McMahon, C. E., Pan, M., Bao, H., Petterson, X.-M. T., Blake, E., Lauer, K. P., O’Brien, D. R., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.041 · Cited by 63
Combination of CCl4 with alcoholic and metabolic injuries mimics human liver fibrosis
Brol, M. J., Rösch, F., Schierwagen, R., Magdaleno, F., Uschner, F. E., Manekeller, S., Queck, A., Schwarzkopf, K. M., Odenthal, M., Drebber, U., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00361.2018 · Cited by 62
Acetaminophen‐Induced Liver Damage in Hepatic Steatosis
García‐Román, R., & Francés, R. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1701 · Cited by 61
Chen, Y., Wang, W., Morgan, M. P., Robson, T., & Annett, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148934 · Cited by 63
The spatial and temporal activation of macrophages during fibrosis
Behmoaras, J. V., Mulder, K., Ginhoux, F., & Petretto, E. G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01186-x · Cited by 75
Zhang, G., Wang, X., Chung, T.-Y., Ye, W., Hodge, L., Zhang, L., Chng, K., Xiao, Y.-F., & Wang, Y. J. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01467-w · Cited by 59
Fibrotic Events in the Progression of Cholestatic Liver Disease
Wu, H., Chen, C., Ziani, S., Nelson, L. J., Avila, M. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Cells · doi:10.3390/cells10051107 · Cited by 62
Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?
Ipsen, D. H., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa081 · Cited by 59
Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes
Jamwal, R., & Barlock, B. J. (2020) · Pharmaceuticals · doi:10.3390/ph13090222 · Cited by 59
Li, W., Shen, Y., Gong, X., Zhang, X., & Yuan, L. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04246 · Cited by 56
Zhou, D., Zhang, J., Xiao, C., Mo, C., & Ding, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964477 · Cited by 61
Tian, Y., Jellinek, M. J., Mehta, K., Seok, S. M., Kuo, S. H., Lu, W., Shi, R., Lee, R. G., Lau, G. W., Kemper, J. K., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000375 · Cited by 60
Xie, W., Gan, J., Zhou, X., Tian, H., Pan, X., Liu, W., Li, X., Du, J., Xu, A., Zheng, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.020 · Cited by 55
ACLY inhibition promotes tumour immunity and suppresses liver cancer
Gautam, J., Wu, J., Lally, J., McNicol, J. D., Fayyazi, R., Ahmadi, E., Oniciu, D. C., Heaton, S., Newton, R. S., Rehal, S., et al. (2025) · Nature · doi:10.1038/s41586-025-09297-0 · Cited by 64
Self-citationLi, Z., Zhang, H., Li, Q., Feng, W., Jia, X., Zhou, R., Huang, Y., Li, Y., Hu, Z., Hu, X., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-02257-1 · Cited by 55
Shen, H., Yu, H., Li, Q., Wei, Y.-T., Fu, J., Dong, H., Cao, D., Guo, L., Chen, L., Yang, Y., et al. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00907-5 · Cited by 58
Tsuchiya, Y., Seki, T., Kobayashi, K., Komazawa‐Sakon, S., Shichino, S., Nishina, T., Fukuhara, K., Ikejima, K., Nagai, H., Igarashi, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42058-z · Cited by 57
Yang, Q., Chen, X., Zhang, Y., Hu, S., Hu, F., Huang, Y., Ma, T., Hu, H., Tian, H., Tian, S., et al. (2021) · Hepatology · doi:10.1002/hep.32061 · Cited by 52
Romualdo, G. R., Leroy, K., Costa, C. J. S., Bacil, G. P., Vanderborght, B., da Silva, T. C., Barbisan, L. F., Andraus, W., Devisscher, L., Câmara, N. O. S., et al. (2021) · Cancers · doi:10.3390/cancers13215583 · Cited by 54
Wan, Z., Yang, X., Liu, X., Sun, Y., Yu, P., Xu, F. L., & Deng, H. (2022) · iScience · doi:10.1016/j.isci.2022.104597 · Cited by 55
Carter, J. K., Bhattacharya, D., Borgerding, J. N., Fiel, M. I., Faith, J. J., & Friedman, S. L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0244763 · Cited by 52
Self-citationNeferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway
Wang, M., Zhang, S.-S., An, M., Xia, Y.-F., Fan, M.-S., Sun, Z., Zhang, L.-J., Zhao, Y., Sheng, J., & Wang, X. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154798 · Cited by 52
Animal models for hepatocellular carcinoma
Zhang, H. E., Henderson, J. M., & Gorrell, M. D. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.009 · Cited by 51
Metadata
- Authors
- Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., & Friedman, S. L.
- Affiliations
- Tanabe Pharma Corporation (Japan) (JP)
- Icahn School of Medicine at Mount Sinai (US)
- Mount Sinai Hospital (US)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 69
- Issue
- 2
- Pages
- 385-395
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC6054570
- OpenAlex
- W2790198401
- Cited by
- 583
- References
- 56
- Citations by year
- 2026: 65 · 2025: 86 · 2024: 90 · 2023: 91 · 2022: 93 · 2021: 62 · 2020: 52 · 2019: 34 · 2018: 10
- FWCI
- 30.84
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-10-01)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Hepatology (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- NIH
- NIDDK (DK099558)
- European Commission (ERC-2014-AdG-671231)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, mouse model, Western diet, carbon tetrachloride, liver fibrosis, hepatocellular carcinoma, liver transcriptome, immune abnormalities, preclinical drug testing
- MeSH terms
- Animals, Carbon Tetrachloride, Disease Models, Animal, Fatty Liver, Inflammation, Liver Cirrhosis, Liver Neoplasms, Mice, Inbred C57BL, Reproducibility of Results, Disease Progression, Gene Expression Profiling, Mice, Diet, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
